trial
as of 2026-07-01A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCTId NCT07105111
at a glance
Phase 4 · Recruiting
Enrollment 50 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2027-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
50 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-08-29
Primary completion
2027-01
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Clinical Development LeadStudy Director
Sites
22 total
Bryant, United StatesChino, United StatesFountain Valley, United StatesFresno, United StatesLong Beach, United StatesOrange, United StatesRedlands, United StatesSan Diego, United StatesBonita Springs, United StatesHialeah, United StatesMiami, United StatesMiami, United States
Facts & assertions
4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2027-01
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator